Zachary Schroeder

Zachary Schroeder

Auto-generated profile, based on publicly available information

Zachary Schroeder

Rural Cancer Institute Staples Minnesota USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2026 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
IJIngrid Jacobson
Ingrid Jacobson
LLLuke Levasseur
Luke Levasseur
LHLaura Hankins
Laura Hankins
AKAryan Kamboj
Aryan Kamboj
ZSZachary Schroeder
Zachary Schroeder

12 July 2023 in The Journal of Rural Health
Verified
Journal Article
Closed access
ZSZachary Schroeder
Zachary Schroeder

21 September 2026 in JCO Oncology Practice
Verified
Journal Article
Open access
WSWade Swenson
Wade Swenson
ZSZachary Schroeder
Zachary Schroeder
Rural Americans with cancer face persistent and widening disparities in incidence, stage at diagnosis, treatment access, and mortality. This paper synthesizes evidence on the financial sustainability of rural oncology programs, the populations bearing the greatest burden of rural cancer disparities, and the care delivery models most likely to narrow those gaps. We conducted a narrative review of English-language literature published through early 2026, drawing from peer-reviewed articles, national surveillance data, ASCO abstracts, and policy analyses. Rural oncology programs face significant financial challenges: 85% of rural hospitals are strained or vulnerable, cancer services at critical access hospitals (CAHs) have declined, and the 340B Drug Pricing Program's orphan-drug exclusion for CAHs represents an underappreciated structural gap that undermines program sustainability for the facilities most dependent on it. Rural-urban cancer mortality gaps are widest among adults younger than 65 years (the age paradox), who lack Medicare's partial safety net. Racial and ethnic minorities in rural areas, particularly Black Americans and American Indian/Alaska Natives, face compounding geographic and structural barriers. Counter to longstanding assumptions, the per-capita supply of rural oncologists grew approximately 20% nationally from 2012 to 2022, with 67% growth in the most isolated areas. Several models show promise, including hub-and-spoke networks, teleoncology, Project Extension for Community Healthcare Outcomes (ECHO) telementoring, CAH-based programs, patient navigation, oncology hospital-at-home, and National Cancer Institute Community Oncology Research Program (NCORP) sites. However, a key paradox persists: regions with the poorest geographic access to cancer centers have the lowest telehealth utilization rates. Rural cancer disparities are fundamentally a policy and equity problem, not a technology or geography problem. Proven delivery models exist, but they require concurrent policy investment to realize their full potential. Closing the gap requires permanent telehealth authorization, with payment parity, Medicaid expansion, advanced practice provider workforce investment, targeted 340B reform for CAHs, and interstate licensure reform. Oncologists and health systems have both the evidence and the ethical obligation to advocate for these changes, including through participation in hub-and-spoke affiliate networks, NCORP sites, or ECHO programs in their own communities.

17 November 2026 in JCO Oncology Practice
Verified
Journal Article
Closed access
WSWade Swenson
Wade Swenson
ASAbigail Swenson
Abigail Swenson
CKCollin Kray
Collin Kray
ASAidan Swenson
Aidan Swenson
GNGillian Northrup
Gillian Northrup
JPJoshua Pritchett
Joshua Pritchett
Purpose: Chemotherapy is widely assumed to be concentrated in urban cancer centers, but state-level data on its geographic distribution are limited. We used the Minnesota All-Payer Claims Database (MN APCD) to characterize rural and urban chemotherapy administration sites, assess quality certification rates, and present a replicable methodology for other states. Methods: Claims for carboplatin (J9045) and paclitaxel (J9264, J9267) from the 2022 MN APCD were analyzed. Chemotherapy administration sites were identified from billing claims, geolocated, and assigned Rural-Urban Commuting Area (RUCA) codes (urban: 1-3; rural: 4-10). Quality Oncology Practice Initiative (QOPI) certification and Commission on Cancer (CoC) accreditation were matched by facility. National QOPI (N = 217) and CoC (N = 1,093) data were analyzed by RUCA category for comparison. Results: Among 104 sites, 55 (52.9%) were rural, accounting for 10,117 (27.0%) of 37,526 claim lines. No rural site held QOPI certification (0% v 16.3% urban). Rural CoC accreditation was lower (25.5% v 42.9%). Nationally, rural practices comprised 14.7% of QOPI-certified sites and 13.4% of CoC-accredited programs, 15%-20% of the US population living in rural areas. Conclusion: Despite published ASCO workforce data showing that only 7%-11.7% of medical oncologists practice in rural areas, 52.9% of Minnesota chemotherapy administration sites are rural, challenging the assumption that chemotherapy delivery is an urban and suburban phenomenon. Rural sites deliver 27.0% of claim volume, suggesting a broadly distributed but lower-intensity rural oncology infrastructure invisible to workforce-based mapping. This APCD-based framework is scalable and replicable; with approximately 25 states operating or developing mandatory APCDs, it can inform cancer control planning, direct resources to where care is delivered, and help close rural oncology disparities nationwide.